Cortès-Saladelafont Elisenda, Molero-Luis Marta, Artuch Rafael, García-Cazorla Àngels
From the *Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain; (†)Institut de Recerca Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain.
CIBER-ER (Biomedical Network Research Center for Rare Diseases), Instituto de Salud Carlos III, Madrid, Spain; Department of Genetics and Biochemistry, Hospital Sant Joan de Déu, Barcelona, Spain.
Semin Pediatr Neurol. 2016 Nov;23(4):351-358. doi: 10.1016/j.spen.2016.11.009. Epub 2016 Nov 10.
Pyridoxal phosphate (PLP) is the active form of vitamin B and a cofactor in many enzyme reactions including neurotransmitter metabolism. PLP metabolism disturbances may mostly lead to refractory seizures. In this report, we review the main pathophysiological factors related with PLP deficiency and our experience in PLP treatment in pediatric patients with low-normal cerebrospinal fluid PLP values who presented epilepsy. Only one case had a definite diagnosis (Phelan-McDermid syndrome). The results of extensive metabolic workups and targeted genetic studies were normal for all patients. In 5 cases, the response to PLP supplementation (10-30mg/kg/d) was initially positive. PLP adverse reactions were noticed in 4 patients and PLP was discontinued; however, one of the most noticeable symptoms was an asymptomatic increase in liver enzymes. These negative results with PLP supplementation are worth reporting, to improve the information we use to treat our patients.
磷酸吡哆醛(PLP)是维生素B的活性形式,也是包括神经递质代谢在内的许多酶反应的辅助因子。PLP代谢紊乱大多可能导致难治性癫痫发作。在本报告中,我们回顾了与PLP缺乏相关的主要病理生理因素,以及我们对脑脊液PLP值略低于正常水平且患有癫痫的儿科患者进行PLP治疗的经验。只有1例有明确诊断(费伦-麦克德米德综合征)。所有患者广泛的代谢检查和针对性基因研究结果均正常。5例患者对PLP补充治疗(10 - 30mg/kg/d)最初反应呈阳性。4例患者出现PLP不良反应并停用PLP;然而,最明显的症状之一是肝酶无症状升高。PLP补充治疗的这些负面结果值得报告,以完善我们用于治疗患者的信息。